ALLMedicine™ Lung Cancer Guidelines Center

Nov 18th, 2022 - This ERS guideline is dedicated to the provision of good quality recommendations in lung cancer care. All the clinical recommendations contained were based on a comprehensive systematic review and evidence syntheses based on eight PICO questions. ...

Aug 2nd, 2022 - There will be a two-part consent, including consent for KRAS testing and consent for treatment on trial. Testing for a KRAS G12C mutation in patients with resectable, stage Ib-IIIa NSCLC is currently not standard of care. Patients who are otherwis...

Aug 24th, 2021 - Timely care is an important dimension of health care quality, but the impact of delays in care on lung cancer outcomes is unclear. Quantifying the impact of delays in cancer treatment on survival is necessary to inform resource allocation, quality...

May 17th, 2021 - In new small cell lung cancer guidelines, the European Society of Medical Oncology calls for upfront atezolizumab or durvalumab in combination with four to six cycles of etoposide and a platinum for stage 4 disease. The strong recommendation is ba.

Oct 19th, 2020 - National guidelines failed to classify many younger African American lung cancer patients as being eligible for lung cancer screening in a recent retrospective study, the lead author reported at the annual meeting of the American College of Chest.

May 10th, 2013 - Continued tobacco use in the setting of lung cancer management is frequently confounding and always of critical importance. We summarized the published literature concerning the management of tobacco dependence in patients with lung cancer and off...

May 10th, 2013 - The objective of this article is to update previous evidence-based recommendations for evaluation and management of individuals with solid pulmonary nodules and to generate new recommendations for those with nonsolid nodules. We updated prior lite...

May 10th, 2013 - Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable, clinical entity in patients given the diagnosis at a time when their performance status (PS) remains good. A systematic literature review was performed to update the prev...

Aug 2nd, 2022 - There will be a two-part consent, including consent for KRAS testing and consent for treatment on trial. Testing for a KRAS G12C mutation in patients with resectable, stage Ib-IIIa NSCLC is currently not standard of care. Patients who are otherwis...

Jun 20th, 2019 - The positive rate of EGFR mutations in lung adenocarcinoma patients is about 50% in both Asian population and China.Domestic and international clinical studies have found that targeted therapy combination chemotherapy can prolong the overall survi...

May 17th, 2021 - In new small cell lung cancer guidelines, the European Society of Medical Oncology calls for upfront atezolizumab or durvalumab in combination with four to six cycles of etoposide and a platinum for stage 4 disease. The strong recommendation is ba.

Dec 5th, 2020 - During the past decade, ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non— small-cell lung cancer (NSCLC) with ALK gene rearrangement...

Dec 5th, 2020 - From tiny biotech firms to giant pharmaceutical companies, the oncology drug development pipeline is pulsing with activity. There are nearly 900 potential new medicines and vaccines to treat cancer under study in the United States, according to th...

Dec 5th, 2020 - Dosing Patterns and Costs of Erythropoesis-Stimulating Agents in Patients With Cancer A retrospective study of nearly 9,000 patients with cancer receiving epoetin alfa or darbepoetin alfa found that costs and dosing regimens varied conside...

Oct 20th, 2020 - National guidelines failed to classify many younger African-American lung cancer patients as being eligible for lung cancer screening in a recent retrospective study, the lead author reported at the annual meeting of the American College of Chest ...